Evidence map›Paper›PMID 29421609›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2018

Colorectal cancer lung metastasis treatment with polymer-drug nanoparticles.

Piotr Rychahou, Younsoo Bae, Derek Reichel, Yekaterina Y Zaytseva, Eun Y Lee, Dana Napier, Heidi L Weiss, Nick Roller, Heather Frohman, Anh-Thu Le and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 66 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Lncrna CASC15 Activated By TCF12 Promote Colorectal Cancer ProgressionCombinatorial chemistry & high throughput screening · 2024
    Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Piotr RychahouMarkey Cancer Center, The University of Kentucky, Lexington, KY 40536, United States; Department of Surgery, The University of Kentucky, Lexington, KY 40536, United States.
Younsoo BaeDepartment of Pharmaceutical Sciences, The University of Kentucky, Lexington, KY 40536, United States.
Derek ReichelDepartment of Pharmaceutical Sciences, The University of Kentucky, Lexington, KY 40536, United States.
Yekaterina Y ZaytsevaMarkey Cancer Center, The University of Kentucky, Lexington, KY 40536, United States.
Eun Y LeeMarkey Cancer Center, The University of Kentucky, Lexington, KY 40536, United States; Pathology and Laboratory Medicine, The University of Kentucky, Lexington, KY 40536, United States.
Dana NapierPathology and Laboratory Medicine, The University of Kentucky, Lexington, KY 40536, United States.
Heidi L WeissMarkey Cancer Center, The University of Kentucky, Lexington, KY 40536, United States.
Nick RollerMarkey Cancer Center, The University of Kentucky, Lexington, KY 40536, United States.
Heather FrohmanMarkey Cancer Center, The University of Kentucky, Lexington, KY 40536, United States; Department of Surgery, The University of Kentucky, Lexington, KY 40536, United States.
Anh-Thu LeMarkey Cancer Center, The University of Kentucky, Lexington, KY 40536, United States; Department of Surgery, The University of Kentucky, Lexington, KY 40536, United States.
B Mark EversMarkey Cancer Center, The University of Kentucky, Lexington, KY 40536, United States; Department of Surgery, The University of Kentucky, Lexington, KY 40536, United States. Electronic address: mark.evers@uky.edu.
University of Kentucky · USMarkey Cancer Center · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Bernard Mark Evers · 2013 to 2026
$38.3M
SURGICAL STUDIES OF FUNCTIONAL GENE EXPRESSIONR01DK048498 · NIDDK · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI EVERS, BERNARD MARK · 1996 to 2023
$7.9M
Novel pRNA Nanoparticle Delivery as Directed Therapy for Colorectal Cancer MetastasisR01CA195573 · NCI · UNIVERSITY OF KENTUCKY · PI EVERS, BERNARD MARK, GUO, PEIXUAN · 2015 to 2019
$1.8M
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA195573NIDDK NIH HHS R01 DK048498
6 · The paper itself

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States; the predominant cause for mortality is metastasis to distant organs (e.g., lung). A major problem limiting the success of chemotherapy in metastatic CRC is the inability to target tumor tissues selectively and avoid severe side effects to normal tissues and organs. Here, we demonstrate polymeric nanoparticles (PNPs) entrapping chemotherapeutic agents provide a new therapeutic option for treating CRC that has metastasized to the lung. PNPs assembled from FDA approved biocompatible block copolymer accumulated predominantly in lung tissue. PNPs showed negligible accumulation in liver, spleen and kidneys, which was confirmed by fluorescent nanoparticle imaging and analysis of PI3K inhibition in the organs. PNPs entrapping PI3K inhibitors (i.e., wortmannin and PX866) suppressed CRC lung metastasis growth, and SN-38-loaded PNPs completely eliminated CRC lung metastasis. Our results demonstrate that polymer-drug nanoparticles offer a new approach to reduce toxicity of cancer therapy and has the potential to improve outcomes for patients with lung metastasis.

Indexed as

AnimalsColorectal NeoplasmsDrug CarriersGonanesHT29 CellsHumansIrinotecanLung NeoplasmsMaleMice, Inbred BALB CMice, NudeMice, SCIDNanoparticlesPhosphoinositide-3 Kinase InhibitorsPolymersTopoisomerase I InhibitorsDrug CarriersGonanesIrinotecanPhosphoinositide-3 Kinase InhibitorsPolymersPX-866Topoisomerase I InhibitorsWortmanninColorectal cancerCRC lung metastasisNanoparticle therapeuticsPI3K inhibitorsPolymeric nanoparticles

Identifiers

PMID29421609
PMCPMC5908241
OpenAlexW2793471550

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.